IFW



Sir:

PATENT Customer No. 60,949 Attorney Docket No. 08702.0097-00000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Yannoni <i>et al.</i>	Group Art Unit: 1653
Application No.: 10/523,014	Examiner: Monshipouri, Maryam
Filed: February 1, 2005	) )
For: MK2 Interacting Proteins	Confirmation No.: 2654
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before a first Office Action on the merits.

Copies of the listed non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law,

Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: June 27, 2007

ames P. Kasten

Reg. No. 51,862

ins	Form	PTO/SR/08	Substitute for form 14	494/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	

		OIPE 40
С	omplete if Known	2007
Application Number	10/523,014	UN 27 LUUI
Filing Date	February 1, 2005	3
First Named Inventor	Yannoni	The same
Art Unit	1653	THAIDS
Examiner Name	Monshipouri, Maryam	
Attorney Docket Number	08702.0097-00000	

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Cite	Cite	te Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No. <sup>1</sup>	Number-Kind Code <sup>2</sup> (if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>	
		Upton, J., "California's non-profit community blood bank system," California Medical Association, 73: 1950-52 (1950).		
		Plath, K., et al., "Characterization of the proline rich region of MAPKAP kinase 2: influence on catalytic properties and binding to the C-ABL SH3 domain in vitro," Biochemical and Biophysical Research Communications, 203: 1188-94 (1994).		
		Supplementary partial European Search Report, mailed May 23, 2007		
		Honma, S., et al. "The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells," Endocrine Journal, 49: 371-77 (2002).		
		Yannoni, Y., et al., "P66sch interacts with MAPKAP kinase 2 and regulates its activity," FEBS Letters, 564: 205-11 (2004).		

	· · · · · · · · · · · · · · · · · · ·		
Examiner	l	Date	
LXamilio		1 Date	
Signature	l e e e e e e e e e e e e e e e e e e e	Considered	1
Signature		Considered	
_			